• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Enrique Conterno - Articles and news items

Boehringer Ingelheim logo

Positive top-line pivotal Phase III data results for empagliflozin

Industry news, News / 7 January 2013 / Boehringer Ingelheim

Top-line results for four completed Phase III clinical trials…

Boehringer Ingelheim logo

Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog

Industry news, News / 7 January 2013 / Boehringer Ingelheim

Announces it will begin remainder of pre-planned clinical trials for LY2605541…

Boehringer Ingelheim logo

Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe

Industry news, News / 25 August 2011 / Boehringer Ingelheim

Marketing Authorisation from the European Commission for Trajenta® (linagliptin)…

Boehringer Ingelheim logo

Linagliptin recommended for approval in the treatment of type 2 diabetes

Industry news, News / 24 June 2011 / Boehringer Ingelheim

Boehringer Ingelheim and Eli Lilly received a positive opinion from the EMA’s medicinal committee…

Eli Lilly logo

BYDUREON™ receivies marketing authorisation in Europe

Industry news, News / 21 June 2011 / Eli Lilly and Company

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to BYDUREON™…

Linagliptin

FDA approves linagliptin tablets for the treatment of type 2 diabetes

Industry news, News / 3 May 2011 / OgilvyHealthPR

Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved linagliptin tablets…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +